<DOC>
	<DOCNO>NCT01338831</DOCNO>
	<brief_summary>The purpose first multi-dose study cancer patient determine maximum tolerate dose ( MTD ) recommend phase II dose ( RP2D ) , characterize safety , tolerability pharmacokinetics profile . Once MTD establish and/or RP2D chosen , study enroll patient expansion portion study .</brief_summary>
	<brief_title>Phase I Study LFA102 Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer Prolactin Receptor-positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>1 . Histologically confirm diagnosis prostate cancer , breast cancer , uterine leiomyoma 2 . Detectable metastasis bone scan , CTscan , MRI . 3 . Presence prolactin receptor primary metastatic tumor ( Dose Escalation ) 4 . Suitable venous access blood sample 1 . Prior treatment antiprolactin receptor antibody 2 . Major surgery within 28 day study treatment 3 . Patients receive radiotherapy â‰¤ 2 week prior start study drug 4 . Prior anaphylactic severe infusion reaction antibody formulations Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>prostate cancer ,</keyword>
	<keyword>breast cancer ,</keyword>
	<keyword>prolactin ,</keyword>
	<keyword>prolactin receptor</keyword>
	<keyword>uterine leiomyoma</keyword>
</DOC>